|
|
Volumn 293, Issue 9, 2005, Pages 1051-
|
|
Antiangiogenic therapy a two-trick pony?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
VASCULOTROPIN;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLORECTAL CANCER;
CYTOTOXICITY;
HUMAN;
MATHEMATICAL MODEL;
NONHUMAN;
PRIORITY JOURNAL;
RECTUM CANCER;
RETINA MACULA DEGENERATION;
SHORT SURVEY;
SOLID TUMOR;
TISSUE ENGINEERING;
TREATMENT FAILURE;
ADJUVANT CHEMOTHERAPY;
ANIMAL;
ARTICLE;
DRUG ANTAGONISM;
DRUG POTENTIATION;
NEOPLASM;
VASCULARIZATION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CHEMOTHERAPY, ADJUVANT;
DRUG SYNERGISM;
HUMANS;
NEOPLASMS;
VASCULAR ENDOTHELIAL GROWTH FACTORS;
|
|
EID: 20044375175
PISSN: 00987484
EISSN: None
Source Type: Journal
DOI: 10.1001/jama.293.9.1051 Document Type: Short Survey |
|
Times cited : (4)
|
|
References (0)
|